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n-Laboratory High-Dose
lopidogrel Loading
o We Need a Mirror of
iamond for “Armida’s Garden”?*
oran Stankovic, MD, PHD,
ilorad Zivkovic, MD
elgrade, Serbia
ual antiplatelet therapy, which consists of aspirin and
lopidogrel, forms the cornerstone of pharmacotherapy
ollowing percutaneous coronary intervention (PCI) with
he goal of reducing stent thrombosis, as well as ischemic
vents related to the underlying coronary artery disease. The
ffects of clopidogrel on patient outcomes have been widely
nvestigated in clinical studies that have involved a range of
reatment regimens. When administered without a loading
ose, clopidogrel 75 mg daily causes maximal inhibition of
latelet aggregation after 3 to 7 days (1). One way to
ncrease the generation of the active metabolite of clopi-
ogrel is to raise the dose of the drug, and several trials have
stablished the benefit of pre-treatment with clopidogrel in
CI (2–5). The PCI-CURE (Clopidogrel in Unstable
ngina to prevent Recurrent Events) trial showed that
See page 550
re-treatment with clopidogrel (300-mg loading dose, fol-
owed by 75 mg daily) in addition to aspirin for a median of
0 days before PCI, compared with aspirin alone, reduced
rimary end point by 30% after 1 month (2). Furthermore,
post-hoc analysis of the CREDO (Clopidogrel for the
eduction of Events During Observation) trial has demon-
trated that for clopidogrel to be fully effective, the loading
ose of 300 mg of clopidogrel should be given at least 15 h
efore intervention (3). Although this dose can be readily
mplemented in patients undergoing elective PCI, it is
roblematic when unplanned intervention is required in an
rgent setting. A higher loading dose with 600 mg of
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ion than the 300-mg dose, and the results of the
SAR–REACT (Intracoronary Stenting and Antithrom-
otic Regimen–Rapid Early Action for Coronary Treat-
ent) trial and ISAR–CHOICE (Intracoronary Stenting
nd Antithrombotic Regimen: Choose Between 3 High
ral Doses for Immediate Clopidogrel Effect) trial suggest
hat if a 600-mg loading dose is chosen, no advantage is
ained by increasing the pre-treatment duration beyond 2 h
4,5). Increasing the dose to 900 mg has been associated
ith marginal increases in the magnitude and speed of
latelet inhibition, but significant differences between the
00- and 900-mg doses have not been demonstrated (5).
hus, regardless of the size of the loading dose, pharmaco-
ynamic studies indicate that 2 h is the minimum pre-
ntervention interval that is necessary to achieve optimal
nhibition of platelet aggregation with clopidogrel. This
pparent threshold in the pharmacodynamic effect of clopi-
ogrel has been attributed to limited intestinal absorption of
he drug, variability in cytochrome P450-dependent enzyme
ctivity and drug–drug interactions (1). Based on available
linical evidence, American College of Cardiology/
merican Heart Association/Society for Cardiovascular
ngiography and Interventions 2009 focused updates of
uidelines on PCI recommend that at least 300 to 600 mg
f clopidogrel should be given as early as possible before or
t the time of primary or nonprimary PCI (6). The
uropean Society of Cardiology guidelines recommend that
300-mg loading dose of clopidogrel should be adminis-
ered at least 6 h before PCI (7). Physicians must take these
ecommendations into consideration while simultaneously
ealing with the realities of clinical practice.
Yet, in a “real-world” setting, only very few patients are
ctually scheduled for elective PCI, whereas most patients
re scheduled for elective diagnostic coronary angiography
CAG) with immediate “ad hoc” PCI procedure when
ndicated. Although not formally approved (although rou-
inely used in many centers worldwide) 2 pre-loading
trategies have been proposed to overcome this problem:
rst, pre-loading with clopidogrel of all patients undergoing
iagnostic CAG (thus, unnecessarily exposing the majority
f patients without indication for PCI to aggressive anti-
latelet medication and potentially causing avoidable bleed-
ng complications), or second, in-laboratory (“in-lab”) clo-
idogrel administration after diagnostic angiography, when
natomy is known and indication for PCI established, but
hen optimal “antithrombotic status” is not achieved. This
trategy was tested in the recent randomized PRAGUE-8
tudy in which 1,028 patients submitted to diagnostic CAG
ere randomized to receive a 600-mg clopidogrel loading
ose more than 6 h prior to the procedure (mean interval
as 20 h) versus a 600-mg loading dose given in-lab at the
ime of PCI following angiography (8). Importantly, only
9% of the initial cohort underwent PCI after angiography.
igh-dose clopidogrel before elective angiography in-
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August 10, 2010:558–60 In-Lab High-Dose Clopidogrel Loadingreased the risk of minor bleeding complications (although
leeding risk in the pre-load group of 6.5% appears to be
xcessive considering the elective nature of the procedures),
hereas the effect on the primary ischemic end point was
ot significant (1.3% vs. 2.8%; p  0.43). The authors
onclude that in patients with chronic stable angina, clopi-
ogrel can be administered safely in the catheterization
aboratory before “planned elective PCI” as well as before
ad hoc” PCI, but not before “planned elective diagnostic
oronary angiography.” Importantly, the sample size of this
tudy was underpowered to detect differences in clinical
utcome in the 298 patients undergoing PCI.
In this issue of the Journal, the main results of the
RMYDA-5 PRELOAD (Antiplatelet therapy for Reduc-
ion of MYocardial Damage during Angioplasty) random-
zed trial are presented by Di Sciascio et al. (9).
Armida is a beautiful enchantress in Torquato Tasso’s
pic poem “Jerusalem Delivered,” who bewitched Rinaldo,
ne of the Crusaders, in a maze in Armida’s garden. The
pell is broken by a mirror of diamond that 2 Christian
nights give to Rinaldo, and his warlike spirit is rekindled
hen he glimpses his reflection and decries what has
ecome of him (10).
In the ARMYDA-5 trial, a total of 409 patients were
andomized to receive a 600-mg clopidogrel loading dose 4
o 8 h before PCI (pre-load group) versus a 600-mg loading
ose given in the catheterization laboratory after CAG, but
rior to PCI (in-lab group); primary end point was 30-day
ajor adverse cardiac events (MACE) incidence. The
uthors found no significant difference in the primary end
oint between the 2 arms (8.8% in-lab vs. 10.3% pre-load;
 0.72), and no significant increased risk of bleeding/
ascular complications was observed in the pre-load arm
5.4% vs. 7.8%; p  0.42). The trial addresses a clinically
elevant question with a randomized controlled trial, and
he results support the in-lab administration of clopidogrel
s a safe alternative to routine pre-treatment given before
nowing a patient’s anatomy.
These observations are interesting and provocative, al-
hough some points from ARMYDA-5 trial are worth
ighlighting.
First, ARMYDA-5 enrolled a mixed patient population,
ncluding consecutive patients with both stable angina (60%)
nd acute coronary syndrome (ACS) (40%), and consequently,
small number of patients was enrolled in each group.
lthough the MACE rate was similar for the total population
8.8% in-lab group vs. 10.3% pre-load group), there was a 60%
ncrease in the MACE rate in ACS patients (16%), which
ould have reached statistical significance if the number of
atients enrolled was higher. Since the MACE rate in patients
ith stable angina using in-lab loading was 5%, it seems that
vents in the in-lab group are mainly driven by the ACS group
in fact, early platelet inhibition is mandatory in such patients
ue to the elevated thrombotic risk, and a full antiplatelet effect
n the case of “ad hoc’’ PCI is desirable and recommended by
uidelines). However, subgroup analysis was performed postoc, not as a pre-specified end point, and unidentified factors
ay exist that explain why patients with ACS had higher event
ates. Thus, further studies are needed before concluding that
n-lab clopidogrel administration is adequate in all cases re-
ardless of clinical presentation.
Second, the results of ARMYDA-5 are somewhat con-
roversial because there is no relationship between clinical
utcomes and higher platelet reactivity as assessed by
erifyNow P2Y12 assay (Accumetrics Inc., San Diego,
alifornia) during PCI and during the “critical” 2 h after
CI. This may represent either a small sample size (result-
ng in relatively small numbers of events) to determine
linical differences in relation to platelet reactivity assess-
ent or the lack of usefulness of this point-of-care mea-
urement in clinical practice. The difference of P2Y12
eaction unit values at the time of PCI reflects the different
iming of clopidogrel loading in the 2 groups; if platelet
eactivity is truly higher in the in-lab group, the concern
ay arise, and a larger trial powered specifically to early
tent thrombosis may be required. Nevertheless, this study
erves the purpose of stimulating more and larger efforts to
tudy the issue of clopidogrel platelet reactivity by develop-
ng either new regimens of the same drug or new drugs that
ave different, more predictable, and more powerful effects
n platelet function, such as prasugrel or ticagrelor. With
hese new compounds, it may no longer be necessary to
onsider pre-treatment, because of more rapid onset and
ore pronounced platelet inhibition than clopidogrel.
Taking into account those limitations, we cannot resist
sking ourselves whether we need our own mirror of
iamond to unravel all the secrets from Armida’s garden.
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